Only in Titles

           Search results for: Recombinant Human IFN α-2b   

paperclip

#31186110   // Save this To Up

Novel glycosylated human interferon alpha 2b expressed in glycoengineered Pichia pastoris and its biological activity: N-linked glycoengineering approach.

Human interferon alpha 2b (IFN α2b) is a type I interferon exhibiting antiviral, anti-proliferative and immunomodulatory activities. The clinical outcome of the approved recombinant human IFN α2b drugs in the market suffers from short plasma half-life, rapid clearance and other side effects. Human IFN α2b expression in mammalian cell lines results in significant heterogeneity in glycan moieties, inconsistent product quality and high production cost. Potential scope exists for the design and development of a successful expression platform for enhanced human IFN α2b production with improved pharmacokinetic property. Glycoengineering strategy was employed to construct IFN α2b with potential N-glycosylation site to evade the drawbacks of approved recombinant human IFN α2b drugs. Heterogeneity of glycosylation and hypermannosylation in the wild-type strains of Pichia pastoris was circumvented by employing glycoengineered strain (SuperMan5) to produce glycosylated IFN α2b with human type N-glycans. Recombinant SuperMan5 strain expressed human type N-glycosylated IFN α2b with greater homogeneity elucidated by glycan analysis (MALDI-TOF/MS). The purified glycosylated IFN α2b was biologically active, inhibiting the viral replication of HCV and HEV at 85% and 66%, respectively. Pharmacokinetic studies in Wistar rats revealed 1.3 fold increase in plasma half-life for glycosylated IFN α2b compared to standard IFN α2b produced by E. coli.

1307 related Products with: Novel glycosylated human interferon alpha 2b expressed in glycoengineered Pichia pastoris and its biological activity: N-linked glycoengineering approach.

Recombinant Human Interfe interferon-alpha receptor Recombinant Human Interfe Interferon alpha-6 antibo Recombinant Human Interfe Interferon alpha-2 antibo Recombinant Human Interfe RANK Ligand Soluble, Huma Recombinant Human Interfe Recombinant Human Interfe Recombinant Human Interfe Interferon alpha-8 antibo

Related Pathways

paperclip

#31158491   // Save this To Up

Therapeutic effectiveness of type I interferon in vulvovaginal candidiasis.

Vulvovaginal candidiasis (VVC) affects approximately 75% of all women of during their reproductive years. Previously, we reported that recombinant human IFN α-2b (rhIFNα-2b) protects vaginal epithelial cells from candidal injury in vitro. In the current study, we examined the effects of rhIFNα-2b (1.25 mg/mL, 10% inhibition concentration) on fungal clearance, immunocompetent cytokine responses, non-B IgG production, and tissue repair in a rat model of VVC. Following rhIFNα-2b treatment, the negative pathogen conversion rate reached 50.0% (3/6). Although rhIFNα-2b exhibited a limited ability to decrease inflammation and injury progression (P > 0.05), the Flameng mitochondrial injury scores were significantly reduced (P < 0.001) compared with those of the Model rats. After rhIFNα-2b treatment, the levels of IFN-γ and epithelial-derived IgG (tested by RP215) in vaginal tissues were significantly increased with those in the Control and Model groups (both P < 0.001), while there were no significant differences in the levels of IL-4 and IL-17 (P > 0.05). This is the first study to address the efficacy of rhIFNα-2b in treating VVC in a rat model, providing a theoretical basis for development of this promising treatment for clinical use.

2034 related Products with: Therapeutic effectiveness of type I interferon in vulvovaginal candidiasis.

Interferon-a Receptor Typ Interferon gamma Rat monoclonal anti mouse Interferon γ Multiple cancer (12 type) FDA Standard Frozen Tissu Recombinant Human Interfe Rabbit Anti-Human Interfe Multiple types of kidney Native Parainfluenza Viru Top 4 types of cancer (co interferon-alpha receptor

Related Pathways

paperclip

#31046700   // Save this To Up

Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China.

Pegylated interferon (PEG-IFN) alfa-2b is recommended for chronic hepatitis B (CHB). We aimed to investigate the sustainability of off-treatment responses among Chinese HBeAg-positive CHB patients treated with PEG-IFN alfa-2b from a randomized trial.

2813 related Products with: Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China.

Goat Anti-Human AOC3, (in Goat Anti- Neudesin NENF, Interleukin-34 IL34 (N-t Goat Anti-Human GAB2, (in Goat Anti-Human TGM2, (in Goat Anti- RASA3 GAP1IP4B Goat Anti-Human HMGB3 HMG Goat Anti-Human, Mouse In Goat Anti-Influenza A H5N Goat Anti-Human CES1, (in Goat Anti-Human GCNT3 (aa Goat Anti-Mouse ATG16L1,

Related Pathways

paperclip

#30560508   // Save this To Up

Diversity of cell phenotypes among MT-2 cell lines affects the growth of U937 cells and cytokine production.

We previously reported the diversity of structure and integration sites of human T-cell leukemia virus type 1 (HTLV-1) provirus among different MT-2 cell lines. This raised the question as to whether cell phenotypes also differed among MT-2 cell lines. The influence of two different MT-2 cell lines (MT-2J and MT-2B) on the growth of the promonocytic leukemia cell line, U937, was investigated. Protein levels and mRNA expression of cytokines were also investigated. In addition, Western blot analysis of HTLV-1 regulatory proteins, Tax and HBZ, was also performed. Culture supernatant from MT-2B, but not MT-2J, cells showed marked suppressive effects on U937 cell growth. MT-2B showed high tumor necrosis factor (TNF)-α, TNF-β, and interferon (IFN)-γ both in protein levels of the culture supernatant and mRNA levels of the cells. Analysis using recombinant cytokines indicated that the suppressive effects of MT-2B were due, at least in part, to high levels of TNF-β and its synergic effects with IFN-γ in the culture supernatant. Protein levels of HTLV-1 Tax and HBZ were higher in MT-2B than those in MT-2J cells. These molecules have been reported to affect the cytokine production of HTLV-1 infected cells; therefore, the difference in these molecules may have accounted for the differences in cytokine production between MT-2J and MT-2B cells. Furthermore, because MT-2 cells showed a large variation of integrated HTLV-1 proviruses as well as cell phenotypes, it is important to exercise caution in the assessment and interpretation of experimental data from MT-2 cells.

1642 related Products with: Diversity of cell phenotypes among MT-2 cell lines affects the growth of U937 cells and cytokine production.

3,3 dioctadecyloxacarbocy Guinea Pig Red Blood Cell Competent Cells for Cloni Mouse Red Blood Cells 25m Canine Red Blood Cells 25 Rabbit Red Blood Cells 25 Macrophage Colony Stimula RARalpha Reporter Cell Li Competent Cells for Cloni 1,1'-Dioctadecyl-3,3,3',3 Epidermal Growth Factor ( Rat Red Blood Cells 25ml

Related Pathways

paperclip

#30543590   // Save this To Up

Novel therapeutic approaches in polycythemia vera.

Polycythemia vera (PV) is the most common Philadelphia chromosome-negative myeloproliferative neoplasm. Whereas low-risk patients are treated with aspirin and phlebotomy, high-risk patients receive cytoreductive therapy, which most commonly consists of hydroxyurea in the United States. Concerns about the long-term safety of hydroxyurea, as well as a desire for more efficacious and targeted therapy, have led to the development of novel therapies for high-risk patients with PV. Pegylated interferon (IFN) has shown promise in phase 2 studies of PV, and preliminary data from ongoing phase 3 studies suggest noninferiority as a frontline therapy. Efficient count control, tolerability, and even molecular responses as a salvage therapy have been demonstrated. Ropeginterferon-α-2b, a monopegylated IFN with a longer half-life and less frequent dose interval compared with recombinant or pegylated IFN, is an impressive agent in development. Ruxolitinib has a proven role as second-line therapy for PV, but an ongoing trial combining ruxolitinib and IFN as salvage therapy is under way. Early-phase clinical trials have also suggested that MDM2 inhibitors such as idasanutlin and histone deacetylase inhibitors should continue in their development. If these novel agents are able to modify the natural history of PV, the treatment paradigm in newly diagnosed patients will evolve from risk-adapted or reactive treatment toward early interventions.

2457 related Products with: Novel therapeutic approaches in polycythemia vera.

FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu Multiple organ tumor tiss FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu RICTOR & RPS6KB1 Protein Rabbit Anti-IAA (Indole-3 ElISA Human , Interleukin Advanced colon cancer tis Goat Anti-Human, Mouse FH

Related Pathways

paperclip

#30344668   // Save this To Up

Therapeutic effect of photodynamic therapy combined with imiquimod in the treatment of anal condyloma acuminatum and its effect on immune function.

Therapeutic effect of photodynamic therapy combined with imiquimod in the treatment of anal condyloma acuminatum (CA) was investigated to explore its effect on immune function. A total of 104 patients with anal CA were randomly divided into two groups: Patients in the study group were treated with photodynamic therapy combined with imiquimod, and ii) patients in the control group were treated with recombinant human interferon α-2b cream. Clinical efficacy and immune function related indicators were compared between the two groups. After treatment for 6 weeks, the cure rate and total effective rate of study group was 53.85 and 92.31%, respectively, which were significantly higher than those of the control group (30.77 and 75.00%, P<0.05). Recurrence rate of study group was 3.85% within 6 months after treatment, which was significantly lower than that of the control group (19.23%, P<0.05). After treatment, levels of CD4, CD4/CD8 and IFN-γ in the study group were significantly higher than those in the control group, and levels of CD8, IL-4 and IL-10 in the study group were significantly lower than those in the control group (P<0.05). Photodynamic therapy combined with imiquimod in the treatment of anus CA can regulate T lymphocyte subsets and cytokine levels, enhance immune function, improve clinical efficacy, reduce recurrence rate, and have almost no side effects. Therefore, this treatment should be popularized in clinical practice.

2937 related Products with: Therapeutic effect of photodynamic therapy combined with imiquimod in the treatment of anal condyloma acuminatum and its effect on immune function.

Multiple organ tumor tiss FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu Normal rat multiple organ Ofloxacin CAS Number [824 Normal rat multiple organ Rabbit Anti-FGF3 Oncogene Syringe pump can be contr

Related Pathways

paperclip

#30213012   // Save this To Up

Efficacy and safety of combined high-dose interferon and red light therapy for the treatment of human papillomavirus and associated vaginitis and cervicitis: A prospective and randomized clinical study.

We evaluated the efficacy and safety of combined high-dose interferon (IFN) and red light therapy for the treatment of subclinical and latent human papillomavirus (HPV) infections.

2359 related Products with: Efficacy and safety of combined high-dose interferon and red light therapy for the treatment of human papillomavirus and associated vaginitis and cervicitis: A prospective and randomized clinical study.

Goat Anti-Human Androgen Rabbit Anti-Human Androge CAR,CAR,Constitutive acti Rabbit Anti-Human Androge Recombinant Human Androge Rabbit Anti-Human Androge (3β)-Androsta-5,16-diene (5α)-Androstane-3,11,17- Rabbit Anti-Rat Androgen 17β-Acetoxy-2α-bromo-5 Androstenedione-19 Antibo Androgen Receptor

Related Pathways

paperclip

#30168073   // Save this To Up

Pegylated interferon-based sequential therapy for treatment of HBeAg reactive pediatric chronic hepatitis B-First study in children.

Our aim was to evaluate the efficacy and safety of sequential therapy using pegylated interferon (Peg-IFN) and nucleos(t)ide analogue (NA) for treatment of children in immunoactive (IA) and immunotolerant (IT) phases of chronic hepatitis B.

2864 related Products with: Pegylated interferon-based sequential therapy for treatment of HBeAg reactive pediatric chronic hepatitis B-First study in children.

interferon-alpha receptor Human E Antigen of Hepati Interferon-γ | Interfer Interferon gamma IgG Rabbit Polyclonal to Interferon-a Receptor Typ Indole 3 carboxaldehyde ( Recombinant Human Interfe Recombinant Ovine Interfe Human Interferon α ELISA Rabbit Anti-Human Interfe Interferon alpha-8 antibo

Related Pathways

paperclip

#30133478   // Save this To Up

Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial).

Current drugs for chronic hepatitis B therapy have a poor efficacy in terms of post-treatment sustained viral suppression and generate important side effects during and after therapy. Therapeutic vaccination with HBV antigens is an attractive alternative to test.

2111 related Products with: Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial).

3-O-Acetyl-17-O-tert-buty Bovine Androstenedione,AS Epiandrosterone (3 beta H 17β-Acetoxy-2α-bromo-5 Rabbit Anti-Rat Androgen Breast tumor survey tissu Breast cancer and normal Breast carcinoma tissue a Androgen Receptor Antibod Hepatitis B Core Antigen Andrographolide CAS Numbe Breast cancer tissue arra

Related Pathways

paperclip

#30055888   // Save this To Up

Cyclic analogue of S-benzylisothiourea that suppresses kynurenine production without inhibiting indoleamine 2,3-dioxygenase activity.

Kynurenine is biosynthesised from tryptophan catalysed by indoleamine 2,3-dioxygenase (IDO). The abrogation of kynurenine production is considered a promising therapeutic target for immunological cancer treatment. In the course of our IDO inhibitor programme, formal cyclisation of the isothiourea moiety of the IDO inhibitor 1 afforded the 5-Cl-benzimidazole derivative 2b-6, which inhibited both recombinant human IDO (rhIDO) activity and cellular kynurenine production. Further derivatisation of 2b-6 provided the potent inhibitor of cellular kynurenine production 2i (IC = 0.34 µM), which unexpectedly exerted little effect on the enzymatic activity of rhIDO. Elucidation of the mechanism of action revealed that compound 2i suppresses IDO expression at the protein level by inhibiting STAT1 expression in IFN-γ-treated A431 cells. The kynurenine-production inhibitor 2i is expected to be a promising starting point for a novel approach to immunological cancer treatment.

1074 related Products with: Cyclic analogue of S-benzylisothiourea that suppresses kynurenine production without inhibiting indoleamine 2,3-dioxygenase activity.

Sheep Anti-Human Indoleam Lipase Activity Assay Kit CLIA Human Serum Renin Ac Asparaginase Activity Ass ELISA kit CLGI,Collagenas Protease Activity Assay K Rapid Microplate Assay K Buyrylcholinesterase Fluo MarkerGeneTM Live Dead As Amplite™ Fluorimetric H Cyclic GMP Direct Chemilu 2, 7 Dichlorofluorescein

Related Pathways